Genesis IBRC India [GENESIS] vs Panacea Biotec [PANACEABIO] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Genesis IBRC India Ltd. wins in 8 metrics, Panacea Biotec Ltd. wins in 6 metrics, with 1 ties. Genesis IBRC India Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Genesis IBRC India Ltd. | Panacea Biotec Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 57.89 | 182.62 | Genesis IBRC India Ltd. |
| Price-to-Book Ratio | 9.93 | 2.65 | Panacea Biotec Ltd. |
| Debt-to-Equity Ratio | 0.00 | 2.79 | Tie |
| PEG Ratio | N/A | -15.02 | N/A |
| EV/EBITDA | 26.95 | -65.87 | Genesis IBRC India Ltd. |
| Profit Margin (TTM) | 2.36% | -1.29% | Genesis IBRC India Ltd. |
| Operating Margin (TTM) | -11.05% | 1.99% | Panacea Biotec Ltd. |
| EBITDA Margin (TTM) | N/A | 1.99% | N/A |
| Return on Equity | 0.08% | -1.01% | Genesis IBRC India Ltd. |
| Return on Assets (TTM) | 0.05% | -0.65% | Genesis IBRC India Ltd. |
| Free Cash Flow (TTM) | $-3,000 | $-776.74M | Genesis IBRC India Ltd. |
| 1-Year Return | 507.27% | -22.18% | Genesis IBRC India Ltd. |
| Price-to-Sales Ratio (TTM) | 1,399.83 | 3.61 | Panacea Biotec Ltd. |
| Enterprise Value | $944.70M | $19.26B | Panacea Biotec Ltd. |
| EV/Revenue Ratio | 326.10 | 3.18 | Panacea Biotec Ltd. |
| Gross Profit Margin (TTM) | N/A | 58.88% | N/A |
| Revenue per Share (TTM) | $0 | $99 | Panacea Biotec Ltd. |
| Earnings per Share (Diluted) | $-0.18 | $-1.28 | Genesis IBRC India Ltd. |
| Beta (Stock Volatility) | N/A | 0.14 | N/A |
Genesis IBRC India Ltd. vs Panacea Biotec Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Genesis IBRC India Ltd. | -4.96% | 0.00% | -0.51% | 54.94% | -14.33% | 37.72% |
| Panacea Biotec Ltd. | 0.70% | 1.54% | 15.38% | 31.92% | 21.66% | 14.02% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Genesis IBRC India Ltd. | 507.27% | 993.55% | 1,467.02% | 623.84% | 5,745.00% | 5,745.00% |
| Panacea Biotec Ltd. | -22.18% | 242.47% | 5.32% | 298.85% | 175.16% | 35.76% |
Performance & Financial Health Analysis: Genesis IBRC India Ltd. vs Panacea Biotec Ltd.
| Metric | GENESIS | PANACEABIO |
|---|---|---|
| Market Information | ||
| Market Cap | ₹4.47B | ₹21.84B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 250 | 168,211 |
| 90 Day Avg. Volume | 317 | 144,184 |
| Last Close | ₹111.10 | ₹433.60 |
| 52 Week Range | ₹19.25 - ₹181.30 | ₹292.40 - ₹495.60 |
| % from 52W High | -38.72% | -12.51% |
| All-Time High | ₹184.90 (Nov 11, 2025) | ₹581.90 (Apr 28, 2025) |
| % from All-Time High | -39.91% | -25.49% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.01% |
| Quarterly Earnings Growth | N/A | -0.12% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | -0.01% |
| Operating Margin (TTM) | -0.11% | 0.02% |
| Return on Equity (TTM) | 0.00% | -0.01% |
| Debt to Equity (MRQ) | 0.00 | 2.79 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹9.02 | ₹134.77 |
| Cash per Share (MRQ) | ₹5.26 | ₹13.86 |
| Operating Cash Flow (TTM) | ₹0 | ₹-1,511,860,000 |
| Levered Free Cash Flow (TTM) | ₹35.05M | ₹-83,700,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Genesis IBRC India Ltd. vs Panacea Biotec Ltd.
| Metric | GENESIS (Apr 24, 2026) | PANACEABIO (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 57.89 | 182.62 |
| Forward P/E | N/A | N/A |
| PEG Ratio | N/A | -15.02 |
| Price to Sales (TTM) | 1,399.83 | 3.61 |
| Price to Book (MRQ) | 9.93 | 2.65 |
| Market Capitalization | ||
| Market Capitalization | ₹4.47B | ₹21.84B |
| Enterprise Value | ₹944.70M | ₹19.26B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 326.10 | 3.18 |
| Enterprise to EBITDA | 26.95 | -65.87 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.14 |
| Book Value per Share (MRQ) | ₹9.02 | ₹134.77 |
Financial Statements Comparison: Genesis IBRC India Ltd. vs Panacea Biotec Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | GENESIS (2025) | PANACEABIO (2025) |
|---|---|---|
| Revenue/Sales | 0 | 4.93B |
| Cost of Goods Sold | 0 | 2.36B |
| COGS % of Revenue | - | 47.9% |
| Gross Profit | 0 | 2.57B |
| Gross Margin | - | 52.1% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 35.05M | -556.12M |
| Operating Margin | - | -11.3% |
| EBITDA | 35.05M | -76.28M |
| EBITDA Margin | - | -1.5% |
| Pre-Tax Income | 35.05M | -79.48M |
| Pre-Tax Income % of Revenue | - | -1.6% |
| Income Tax | 0 | 7.71M |
| Income Tax % of Revenue | - | 0.2% |
| Net Income (Profit) | 35.05M | -87.19M |
| Profit Margin | - | -1.8% |
Balance Sheet & Liquidity Metrics
| Metric | GENESIS (2025) | PANACEABIO (2025) |
|---|---|---|
| Cash & Equivalents | 57,000 | 821.25M |
| Total Current Assets | 88.35M | 5.45B |
| Total Current Assets % of Revenue | - | 110.7% |
| Total Current Liabilities | 3.03M | 3.67B |
| Total Current Liabilities % of Revenue | - | 74.5% |
| Long-Term Debt | N/A | 150.00M |
| Long-Term Debt % of Revenue | - | 3.0% |
| Total Shareholders Equity | 85.33M | 8.31B |
| Retained Earnings | -83.06M | 7.80B |
| Retained Earnings % of Revenue | - | 158.3% |
| Property, Plant & Equipment | N/A | 5.43B |
Cash Flow Statement Comparison
| Metric | GENESIS (2025) | PANACEABIO (2025) |
|---|---|---|
| Operating Cash Flow | 0 | -1.51B |
| Operating Cash Flow % of Revenue | - | -30.7% |
| Capital Expenditures | N/A | -497.30M |
| Free Cash Flow | -3,000 | -776.74M |
| FCF Margin | - | -15.8% |
| Debt Repayment | N/A | 0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GENESIS | PANACEABIO |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 45.25M | 61.25M |
| Float Shares | N/A | 15.42M |
| % Held by Insiders | 27.24% | 72.65% |
| % Held by Institutions | 0.00% | 0.13% |
| % Held by Public | 72.76% | 27.22% |
Dividend Analysis & Yield Comparison: Genesis IBRC India Ltd. vs Panacea Biotec Ltd.
| Metric | GENESIS | PANACEABIO |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |